Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
Background. A meningococcal group A conjugate vaccine, PsA-TT (MenAfriVac), developed through the Meningitis Vaccine Project and manufactured by the Serum Institute of India, Ltd, was tested in multiple clinical trials conducted mainly in Africa. The impact of age at which subjects were vaccinated o...
Main Authors: | Tang, Yuxiao, Plikaytis, Brian D., Preziosi, Marie-Pierre, Borrow, Ray |
---|---|
Format: | Online |
Language: | English |
Published: |
Oxford University Press
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639503/ |
Similar Items
-
MenAfriVac as an Antitetanus Vaccine
by: Borrow, Ray, et al.
Published: (2015) -
Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
by: Roy Chowdhury, Panchali, et al.
Published: (2015) -
Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
by: Tapia, Milagritos D., et al.
Published: (2015) -
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
by: Tapia, Milagritos D., et al.
Published: (2015) -
Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
by: Karachaliou, Andromachi, et al.
Published: (2015)